Home/Filings/4/0001348362-25-000001
4//SEC Filing

BUNKA CHRISTOPHER 4

Accession 0001348362-25-000001

CIK 0001348362other

Filed

Jan 9, 7:00 PM ET

Accepted

Jan 10, 11:52 AM ET

Size

14.8 KB

Accession

0001348362-25-000001

Insider Transaction Report

Form 4
Period: 2025-01-07
BUNKA CHRISTOPHER
DirectorChariman/CEO/President/CFO
Transactions
  • Award

    Restricted Stock Award

    2025-01-07+100,000373,543 total
Holdings
  • common shares

    (indirect: Private Holding Company)
    254,412
  • Warrants

    (indirect: Private Holding Company)
    Exercise: $10.50From: 2020-05-06Exp: 2025-05-06Common Shares (6,667 underlying)
    6,667
  • Stock Options

    Exercise: $1.15From: 2023-10-26Exp: 2028-10-26Common Shares (30,000 underlying)
    131,001
  • Stock Options

    Exercise: $2.36From: 2024-04-26Exp: 2029-04-26Common Shares (49,500 underlying)
    180,501
  • common shares

    273,543
  • Stock Options

    Exercise: $3.00From: 2021-04-26Exp: 2026-04-26Common Shares (26,000 underlying)
    32,667
  • Stock Options

    Exercise: $3.00From: 2021-06-08Exp: 2026-06-08Common Shares (23,334 underlying)
    56,001
  • Stock Options

    Exercise: $3.00From: 2021-09-01Exp: 2026-09-01Common Shares (15,000 underlying)
    71,001
  • Stock Options

    Exercise: $2.91From: 2022-08-29Exp: 2027-08-29Common Shares (30,000 underlying)
    101,001
Footnotes (2)
  • [F1]Beneficial ownership reflects the aggregate securities held directly.
  • [F2]The closing price on the Issuer's shares on the date of grant was $2.24.

Issuer

Lexaria Bioscience Corp.

CIK 0001348362

Entity typeother

Related Parties

1
  • filerCIK 0001103780

Filing Metadata

Form type
4
Filed
Jan 9, 7:00 PM ET
Accepted
Jan 10, 11:52 AM ET
Size
14.8 KB